Page 5 - Pharma Sctors

Pharma sector must focus on innovation to become global leader: Minister

Union health minister Mansukh Mandaviya on Tuesday asked domestic pharmaceutical industry to focus on the research and development of innovative products to move up the value chain and achieve global leadership. Mandaviya, who also holds the Chemical and Fertilisers portfolio, asked medical technology companies to produce critical equipment in India for the global markets. While formally unveiling the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector here, Mandaviya said the domestic pharmaceutical companies invest less on research and development when compared to multinational companies. "International MNCs spend 20-25 per cent of their profits in research and innovation while for Indian companies the average is around 10 per cent...Till the time we do not come out with research-led innovative products, we cannot lead the segment globally," he noted. He said the government wants to make the pharma industry self-reliant by 2047. "Today is a ...

Genpharmasec to acquire 70% stake in DHPL in phased manner over one year

Incorporated in 1992, Generic Pharmasec Limited started as a manufacturer and trader of organic and inorganic chemicals, dyes, and pigments

Indian pharma Industry to log 8-10% revenue growth in FY24: Report

Drugs in the National List of Essential Medicines contribute 17% of revenue: ICRA

Why small and microcaps are rocketing

The question on everyone's mind is, will this be sustainable? The answer is not simple

Tabreed to invest $200 mn in Telangana to develop district cooling plants

Tabreed, a UAE-based global leader in cooling utilities, on Wednesday said it has partnered with Telangana government to develop cooling infrastructure for industrial and commercial parks, and will invest USD 200 million to develop 1,25,000 RT (refrigeration tonne) of district cooling plants for Hyderabad Pharma City. The state government also signed a MoU with Tabreed to explore district cooling infrastructure in existing and upcoming commercial districts of Cyberabad near here and other mixed use development areas. Speaking on the occasion, Telangana Urban Development, Industries and Commerce Minister K T Rama Rao said, "As we embark on a journey towards a more sustainable future, we are delighted to partner with Tabreed, exemplifying Government of Telangana's commitment to environmental stewardship through embracing innovative and implementable solutions." Tabreed chairman Khaled Abdulla Al Qubaisi said,"By bringing our expertise in district cooling to the world's largest net zer

Cipla, Glenmark: Time to accumulate pharma stocks on robust bullish trend?

The current volatility in the benchmark indices offer the ideal opportunity to accumulate pharma stocks around their respective supports

A critical lapse in Jan Vishwas Bill

In seeking to make life easier for entrepreneurs, the proposed new law raises several questions on patient safety

Nirma looks to raise up to Rs 7,000 crore to fund buys and expansion

The unlisted company posted revenues to the tune of Rs 11,403 crore in fiscal 2023

Waiver for rare disease drugs brings little relief: Pharma sector

Industry bats for extending exemption to drugs that are already commercially available in India

Schedule M of Drugs and Cosmetics Act to be made must for all pharma units

Govt wants units to move towards GMP through self regulation

Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

'4IR': The booster pharma majors are taking to improve productivity

Large manufacturers are leveraging new-age technologies and advanced analytics to improve productivity and reduce deviations in production processes

Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak

Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450

Lupin likely to demerge its active pharmaceutical ingredients business

As such the API business contributes around 7 percent to Lupin's overall turnover

Self-regulatory body for pharma industry on cards: Mansukh Mandaviya

Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants

Fewer Indian pharma plants get US FDA action notice in 2023, so far

6 per cent of inspections in first 6 months of CY23 resulted in OAI status

Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD

Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services

Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data

Focus on profitability, and less options other reasons behind the slowdown seen till May this year

USFDA inspections of Indian sites still below pre-Covid-19 levels

On an average Indian sites have had only a 9% share of total global inspections, analysts point out

India's contribution to global clinical trials at 4% during 2010-22: Study

Trials sponsored by top 20 pharma companies increased 10% since 2013